CX3CR1 and atherosclerosis: A 30mg/kg dose of this “nanobody”, named BI665088, which was developed by AblynxTM in collaboration with Boehringer IngelheimTM was shown to inhibit atherosclerosis development in mice with knock-in human CX3CR1 expression.